Garry A. Neil's Insider Trades & SAST Disclosures

Garry A. Neil's most recent trade in Celldex Therapeutics Inc. was a trade of 16,500 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 5, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Celldex Therapeutics Inc.
Garry A. Neil Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2025 16,500 16,500 - - Non-Qualified Stock Option (right to buy)
Avalo Therapeutics Inc
Garry A. Neil Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Mar 2025 64,867 129,733 - - Restricted Stock Units
Avalo Therapeutics Inc
Garry A. Neil Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Mar 2025 64,867 64,927 - - Common Stock
Avalo Therapeutics Inc
Garry A. Neil Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. 28 Mar 2025 17,787 47,140 - 8.5 150,478 Common Stock
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2025 411,000 411,000 - - Stock Option (Right to Buy)
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Aug 2024 500,400 500,400 - - Stock Option (Right to Buy)
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Aug 2024 194,600 194,600 - - Restricted Stock Units
Celldex Therapeutics Inc.
Garry A. Neil Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Jun 2024 16,500 16,500 - - Non-Qualified Stock Option (right to buy)
Celldex Therapeutics Inc.
Garry A. Neil Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 11,300 11,300 - - Non-Qualified Stock Option (right to buy)
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Purchase of securities on an exchange or from another person at price $ 3.42 per share. 09 Jun 2023 4,000 13,220 - 3.4 13,680 Common Stock
Zura Bio Ltd - Ordinary Sh...
Garry A. Neil Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 May 2023 7,652 7,652 - - Employee Share Option (Right to Buy)
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 May 2023 100,000 100,000 - - Stock Option (Right to Buy)
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Feb 2023 100,000 100,000 - - Stock Option (Right to Buy)
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Purchase of securities on an exchange or from another person at price $ 4.42 per share. 09 Dec 2022 2,083 9,220 - 4.4 9,207 Common Stock
Avalo Therapeutics Inc
Garry A. Neil Director, CEO and Chairman of the Board Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Oct 2022 75,000 75,000 - - Stock Option (Right to Buy)
Celldex Therapeutics Inc.
Garry A. Neil Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 27,200 27,200 - - Non-Qualified Stock Option (right to buy)
Avalo Therapeutics Inc
Garry A. Neil Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Mar 2022 1,000,000 1,000,000 - - Stock Option (Right to Buy)
Avalo Therapeutics Inc
Garry A. Neil Chief Scientific Officer Purchase of securities on an exchange or from another person at price $ 1.57 per share. 10 Dec 2021 4,267 85,639 - 1.6 6,699 Common Stock
Avalo Therapeutics Inc
Garry A. Neil Chief Scientific Officer Purchase of securities on an exchange or from another person at price $ 2.28 per share. 10 Jun 2021 3,692 81,372 - 2.3 8,418 Common Stock
Avalo Therapeutics Inc
Garry A. Neil Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2021 260,000 260,000 - - Stock Option (right to buy)
Avalo Therapeutics Inc
Garry A. Neil Chief Scientific Officer Purchase of securities on an exchange or from another person at price $ 2.28 per share. 10 Dec 2020 3,599 77,680 - 2.3 8,199 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades